Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

110.71 +1.12 (+1.02%)
Official Closing Price Updated: 7:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,160,434
Open 109.31
Bid (Size) 102.31 (1)
Ask (Size) 113.26 (1)
Prev. Close 109.59
Today's Range 109.29 - 110.73
52wk Range 96.06 - 120.92
Shares Outstanding N/A
Dividend Yield 3.41%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Prediction: This "Magnificent Seven" Stock Will Be the Most Valuable Company in the World in 10 Years
This company stands to benefit from the advances in artificial intelligence more than any other business. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lazard Transforms Mutual Fund Into IEQ ETF Amid Rising Demand For International Stocks
IEQ inherits the portfolio DNA of its mutual fund ancestor, now in the tax-efficient wrapper increasingly favored by investors. 
Via Benzinga
Topics ETFs

Performance

YTD
+14.0%
+14.0%
1 Month
+0.2%
+0.2%
3 Month
+3.8%
+3.8%
6 Month
+7.4%
+7.4%
1 Year
+7.7%
+7.7%

More News

Read More
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Via Benzinga
Earnings Scheduled For April 29, 2025
Via Benzinga
Earnings Preview For Novartis
Via Benzinga
Here's My Favorite High-Dividend ETF to Buy Right Now
Via The Motley Fool
Topics ETFs
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say
Via Stocktwits
Topics ETFs Government Stocks
Exposures Political US Equities
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study
Via Benzinga
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight
Via Benzinga
Exposures Product Safety
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
Via Benzinga
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead
Via Stocktwits
Topics Stocks
Exposures US Equities
Humana Does Not Alter 2025 Outlook Despite Sales Miss And Medicare Membership Decline
Via Benzinga
Topics Earnings
Exposures Financial
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Via Benzinga
AppLovin Stock Tumbles After Edgewater Research Cuts Estimates Citing Rising Competition
Via Stocktwits
Topics Artificial Intelligence
Exposures Artificial Intelligence
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis
Via Stocktwits
Novartis Q1 Earnings Beat Street View, CEO 'Confident' In Delivering Upgraded Guidance
Via Benzinga
Topics Earnings
Exposures Financial
Novartis Creeps Toward A Breakout On Its Beat-And-Raise
Via Investor's Business Daily
Exposures Product Safety
US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week
Via Benzinga
General Motors, Coca-Cola And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report
Via Stocktwits
Topics Government Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
Via MarketBeat
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Economy Political
The Smartest International Stock ETF to Buy With $100 Right Now
Via The Motley Fool
Topics ETFs Economy
Exposures Economy
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?
Via The Motley Fool
Topics Economy Government Lawsuit
Exposures Financial Interest Rates Legal
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill

Frequently Asked Questions

Is Novartis AG Common Stock publicly traded?
Yes, Novartis AG Common Stock is publicly traded.
What exchange does Novartis AG Common Stock trade on?
Novartis AG Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novartis AG Common Stock?
The ticker symbol for Novartis AG Common Stock is NVS on the New York Stock Exchange
What is the current price of Novartis AG Common Stock?
The current price of Novartis AG Common Stock is 110.71
When was Novartis AG Common Stock last traded?
The last trade of Novartis AG Common Stock was at 05/19/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.